SCHEMBL3048207

SCHEMBL3048207

Cc1cccc(Cl)c1C(C(=O)O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK1 Q15118 1/20 0.39
PDK2 Q15119 1/20 0.39
PDK3 Q15120 1/20 0.39
PDK4 Q16654 1/20 0.39
ATM Q13315 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
FABP3 P05413 1/20 0.35
FABP4 P15090 1/20 0.35
PTGS2 P35354 1/20 0.35
ITGB1 P05556 2/20 0.34
ITGA4 P13612 2/20 0.34
ITGA2 P17301 1/20 0.34
ITGB7 P26010 1/20 0.34
TSHR P16473 1/20 0.34
AKR1B1 P15121 1/20 0.34
HPGD P15428 2/20 0.34
HDAC4 P56524 1/20 0.34
LMNA P02545 1/20 0.34
POLB P06746 1/20 0.34
CXCL8 P10145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3060819 0.77 CXCL8 (0.46) FABP3FABP4PTGS2TSHRAKR1B1
SCHEMBL13616663 0.77 LMNA (0.41) PDK1PDK2PDK3PDK4L3MBTL1
SCHEMBL18415642 0.73 CA1 (0.34) PDK1PDK2PDK3PDK4ATM
SCHEMBL18415638 0.73 CA1 (0.34) PDK1PDK2PDK3PDK4ATM
SCHEMBL9716063 0.72 CPN1 (0.43) PTGS2ITGB1ITGA4ITGA2ITGB7
SCHEMBL28608573 0.69 CXCL8 (0.48) PDK1PDK2PDK3PDK4TSHR
SCHEMBL19979060 0.69 ALDH1A1 (0.37) ATMTSHRHDAC4LMNACXCL8
SCHEMBL7953281 0.69 HSP90AA1 (0.41) ATML3MBTL1PTGS2HPGDALDH1A1
SCHEMBL16939393 0.69 CA1 (0.37) TSHRLMNACXCL8ALDH1A1KDM4E
SCHEMBL16939398 0.69 CA1 (0.37) TSHRLMNACXCL8ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders UCB PHARMA, S.A. (BE) 2010-09-02 US claimed
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders UCB PHARMA, S.A. (BE) 2010-09-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222326-A1 New Heterocyclic Derivatives Useful For The Treatment of CNS Disorders CNR2, CNR1, SLC18A2 PDK1 1242/4885PDK2 1294/4885PDK3 1558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.